loading page

ChatGPT in pharmacometrics? Potential opportunities and limitations
  • +2
  • Michael Cloesmeijer,
  • Alexander Janssen,
  • Sjoerd Koopman,
  • Marjon Cnossen,
  • Ron Mathot
Michael Cloesmeijer
Amsterdam UMC Locatie AMC

Corresponding Author:m.e.cloesmeijer@amsterdamumc.nl

Author Profile
Alexander Janssen
Amsterdam UMC Locatie AMC
Author Profile
Sjoerd Koopman
Amsterdam UMC Locatie AMC
Author Profile
Marjon Cnossen
Erasmus University Medical Center - Sophia Children's Hospital
Author Profile
Ron Mathot
Amsterdam UMC - Locatie AMC
Author Profile

Abstract

The potential of using chatGPT in pharmacometrics was explored in this study, with a focus on developing a pharmacokinetic (PK) model for standard half-life factor VIII. Our results demonstrated that chatGPT can be utilized to accurately obtain typical PK parameters from literature, generate a population PK model in R, and develop an interactive Shiny application to visualize the results. ChatGPT’s language generation capabilities enabled the development of R codes with minimal programming knowledge and helped identify and fix errors in the code. While chatGPT presents several advantages, such as its ability to streamline the development process, its use in pharmacometrics also has limitations and challenges, including the accuracy and reliability of AI-generated data, the lack of transparency and interpretability of AI. Overall, our study demonstrates the potential of using chatGPT in pharmacometrics, but researchers must carefully evaluate its use for their specific needs.
21 Apr 2023Submitted to British Journal of Clinical Pharmacology
24 Apr 2023Submission Checks Completed
24 Apr 2023Assigned to Editor
24 Apr 2023Review(s) Completed, Editorial Evaluation Pending
27 Apr 2023Reviewer(s) Assigned
17 May 2023Editorial Decision: Revise Major
31 Jul 20231st Revision Received
01 Aug 2023Submission Checks Completed
01 Aug 2023Assigned to Editor
01 Aug 2023Review(s) Completed, Editorial Evaluation Pending
02 Aug 2023Reviewer(s) Assigned
17 Aug 2023Editorial Decision: Accept